Human Trials

Trialbee and TriNetX partner to accelerate patient-centric clinical trials

Trialbee, a world-leading technology provider in patient matching and engagement, is partnering with TriNetX, a leading global real-world health research network comprised of >170M patients across 23 countries to support data-driven digital solutions to accelerate patient-centric clinical trials.

Forbius completes enrollment into phase 1a solid tumour trial of AVID200

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy has fully enrolled.

MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgaris

Roche said that the phase 3 PEMPHIX trial of MabThera (rituximab) in moderate to severe pemphigus vulgaris (PV) met its primary endpoint at Week 52.

Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis

Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis

Gilead Sciences and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.

Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, announced today that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results. IONIS-FXI-LRx is an antisense medicine being developed to treat patients with clotting disorders.

Dermira begins phase 3 programme to assess lebrikizumab in patients with moderate-to-severe atopic dermatitis

Dermira, a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced dosing of the first patient in a Phase 3 study evaluating the safety and efficacy of lebrikizumab in adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis, the most common form of eczema.

IDEAYA announces first patient dosing of IDE196 for solid tumors outside of uveal melanoma

IDEAYA Biosciences has dosed its first patient with cutaneous melanoma harboring a GNAQ or GNA11 (GNAQ/11) mutation, a key milestone for evaluating Protein Kinase C (PKC) inhibitor IDE196 in solid tumors outside of metastatic uveal melanoma (MUM) as part of IDEAYA's ongoing Phase 1/2 clinical trial entitled "Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions".

Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema

Hoth Therapeutics, a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, announced that they have completed Phase I of their In-Life dose escalation study.